CD38 and Miyoshi myopathy: Preclinical and early clinical evidence demonstrates that CAR-NK cells targeting MM-associated antigens such as BCMA, GPRC5D, NKG2D, CD38, CD70, CD138, and SLAMF7 can mediate potent, selective cytotoxicity with minimal toxicity.